ClinicalTrials.gg
CompletedNCT01651949Updated Nov 27, 2018Results posted

Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)

A Phase 3 interventional study of 9vHPV Vaccine in Genital Warts, Anal Cancer and Anal Intraepithelial Neoplasia, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 16 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-27.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,520
Allocation
Non-randomized
Ages
16 Years to 26 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata — 2 open to participants now, 4 under way, 3 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Condylomata Acuminata.

Enrollment
2nd of 10
2,520 · median 1,206
Started
2012
the only one that year
Phase 3
9 of 10
1 open now
Registered
2nd of 10
by date
Lead sponsor
6 of 10
Merck Sharp & Dohme LLC

Among the 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata, this one is the 2nd largest by enrollment, is the only one that started in 2012, is one of 9 in phase 3, and was the 2nd registered.

Condylomata Acuminata

116 studies on the registry are indexed under Condylomata Acuminata; 11 are open to participants now.

Browse Condylomata Acuminata studies →

Open to participants now

2 of the 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Human Papillomavirus Recombinant Vaccine nonavalent

Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 6 Condylomata Acuminata studies recruiting now, 1 sets no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 16 Years to 26 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata, or all of them as a file.
02

Study summary

This study is designed to evaluate the immunogenicity and tolerability of 9vHPV (9-valent HPV vaccine, V503) in 16- to 26-year old men and women. The overall goal is to bridge 9vHPV efficacy findings in young women to young men based on the demonstration of similar immunogenicity and safety profiles. The primary hypothesis is that 9vHPV induces antibody responses at 4 weeks postdose 3 in heterosexual males that are non-inferior to antibody responses in young women.

Read the detailed description

Study participants will be administered a 3-dose regimen of 9vHPV. They will be assessed for immunogenicity 1 month following completion of vaccination. All participants will be followed for safety for a total of 12 months.

03

Conditions studied

  • Genital Warts
  • Anal Cancer
  • Anal Intraepithelial Neoplasia
04

Who can participate

Ages eligible
16 Years to 26 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Good physical health
  • Has never had Papanicolaou testing (Pap, cervical or anal) or has only had normal Pap test results
  • Other inclusion criteria will be discussed with the investigator

Exclusion criteria

Exclusion Criteria:

  • History of severe allergic reaction that required medical intervention
  • Currently enrolled in a clinical trial
  • If participant is female, pregnant
  • Currently or having received immunosuppressive therapy in the last year
  • Positive test for HPV
  • History of HPV-related external genital lesions or HPV-related anal lesions or anal cancer
  • If participant is female, history of abnormal cervical results
  • Other exclusion criteria will be discussed with the investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,520 participants (actual)

Study arms

  • Active comparator
    Females

    Healthy females 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6

    Biological: 9vHPV Vaccine

  • Experimental
    Heterosexual Males

    Healthy heterosexual males 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6

    Biological: 9vHPV Vaccine

  • Experimental
    Men who have Sex with Men

    Healthy MSM 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6

    Biological: 9vHPV Vaccine

Interventions

  • Biological9vHPV Vaccine

    9vHPV, V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3-dose regimen

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titers (GMTs) to the HPV Types Contained in the 9vHPV Vaccine

    Serum antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL

    Time frame: Four weeks post vaccination 3 (Month 7)

  2. Percentage of Participants With One or More Injection-site Adverse Experiences Prompted on the Vaccination Report Card

    An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Injection-site AEs prompted on the Vaccination Report Card (VRC) were erythema, pain, and swelling. Participants were instructed to use the Vaccination Report Card to record AEs daily after each study vaccination.

    Time frame: Up to 5 days after any vaccination

  3. Percentage of Participants With Elevated Oral Body Temperature (>=37.8° C, >=100° F)

    Participants were instructed by the investigator to use the Vaccination Report Card to document evening oral temperature daily after each study vaccination

    Time frame: Up to 5 days after any vaccination

  4. Percentage of Participants With an Adverse Event

    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE.

    Time frame: Up to Month 12

  5. Percentage of Participants Who Had Study Vaccine Discontinued Due to an Adverse Event

    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE.

    Time frame: Up to Month 12

Secondary outcomes

  1. Percentage of Participants With Seroconversion to the HPV Types Contained in the 9vHPV Vaccine

    Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24; HPV Type 31: ≥10; HPV Types 33, 45, 52, and 58: ≥8.

    Time frame: Four weeks post vaccination 3 (Month 7)

07

Results

Posted Mar 9, 2015

Participant flow

Participant flow — Overall Study
MilestoneHeterosexual MalesFemalesMen Who Have Sex With Men (MSM)
Started11061101313
Vaccination 111031099313
Vaccination 210891069298
Vaccination 310671037291
Completed10531015282
Not completed538631
Withdrew: Unknown status440
Withdrew: Lost to follow-up305620
Withdrew: Protocol violation021
Withdrew: Physician decision020
Withdrew: Adverse event021
Withdrew: Screen failure220
Withdrew: Withdrawal by subject17189

Outcome measures

PrimaryGeometric Mean Titers (GMTs) to the HPV Types Contained in the 9vHPV Vaccine

Serum antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL

Time frame:
Four weeks post vaccination 3 (Month 7)
Reported as:
Geometric mean · milli Merck Units/mL
Geometric Mean Titers (GMTs) to the HPV Types Contained in the 9vHPV Vaccine
milli Merck Units/mLHeterosexual MalesFemalesMen Who Have Sex With Men
Anti-HPV Type 6 (n=847, 708, 164)782.0 (738.0 to 828.7)703.9 (660.6 to 749.9)568.9 (498.7 to 649.0)
Anti-HPV Type 11 (n=851, 712, 165)616.7 (582.4 to 653.0)564.9 (530.6 to 601.3)437.7 (384.4 to 498.5)
Anti-HPV Type 16 (n=899, 781, 212)3346.0 (3158.9 to 3544.1)2788.3 (2621.4 to 2965.8)2294.0 (2037.8 to 2582.5)
Anti-HPV Type 18 (n=906, 831, 220)808.2 (754.9 to 865.4)679.8 (633.1 to 730.1)608.1 (529.4 to 698.5)
Anti-HPV Type 31 (n=908, 826, 227)708.5 (662.7 to 757.6)570.1 (531.5 to 611.5)420.7 (368.0 to 480.9)
Anti-HPV Type 33 (n=901, 853, 230)384.8 (362.5 to 408.4)322.0 (302.9 to 342.3)252.3 (224.2 to 283.8)
Anti-HPV Type 45 (n=909, 871, 232)235.6 (219.0 to 253.6)185.7 (172.3 to 200.2)157.5 (136.2 to 182.2)
Anti-HPV Type 52 (n=907, 849, 232)386.8 (363.4 to 411.6)335.2 (314.3 to 357.6)233.1 (206.0 to 263.7)
Anti-HPV Type 58 (n=897, 839, 223)509.8 (479.9 to 541.6)409.3 (384.5 to 435.7)319.8 (283.2 to 361.0)
Statistical analysis
  • Heterosexual Males vs Females · ANOVA · p = <0.001 · Gmt ratio: 1.11 · 95% CI 1.02 to 1.21An analysis of variance model with a response of log individual titers and fixed effect for group was used.
  • Heterosexual Males vs Females · ANOVA · p = <0.001 · Gmt ratio: 1.09 · 95% CI 1.00 to 1.19An analysis of variance model with a response of log individual titers and fixed effect for group was used
  • Heterosexual Males vs Females · ANOVA · p = <0.001 · Gmt ratio: 1.20 · 95% CI 1.10 to 1.30An analysis of variance model with a response of log individual titers and fixed effect for group was used
  • Heterosexual Males vs Females · ANOVA · p = <0.001 · Gmt ratio: 1.19 · 95% CI 1.08 to 1.31An analysis of variance model with a response of log individual titers and fixed effect for group was used
  • Heterosexual Males vs Females · ANOVA · p = <0.001 · Gmt ratio: 1.24 · 95% CI 1.13 to 1.37An analysis of variance model with a response of log individual titers and fixed effect for group was used
  • Heterosexual Males vs Females · ANOVA · p = <0.001 · Gmt ratio: 1.19 · 95% CI 1.10 to 1.30An analysis of variance model with a response of log individual titers and fixed effect for group was used
  • Heterosexual Males vs Females · ANOVA · p = <0.001 · Gmt ratio: 1.27 · 95% CI 1.14 to 1.41An analysis of variance model with a response of log individual titers and fixed effect for group was used
  • Heterosexual Males vs Females · ANOVA · p = <0.001 · Gmt ratio: 1.15 · 95% CI 1.05 to 1.26An analysis of variance model with a response of log individual titers and fixed effect for group was used
  • Heterosexual Males vs Females · ANOVA · p = <0.001 · Gmt ratio: 1.25 · 95% CI 1.14 to 1.36An analysis of variance model with a response of log individual titers and fixed effect for group was used
PrimaryPercentage of Participants With One or More Injection-site Adverse Experiences Prompted on the Vaccination Report Card

An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Injection-site AEs prompted on the Vaccination Report Card (VRC) were erythema, pain, and swelling. Participants were instructed to use the Vaccination Report Card to record AEs daily after each study vaccination.

Time frame:
Up to 5 days after any vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With One or More Injection-site Adverse Experiences Prompted on the Vaccination Report Card
Percentage of ParticipantsHeterosexual and MSM MalesFemales
Overall injection-site AEs66.784.0
Injection-site Erythema20.732.2
Injection-site Pain63.482.5
Injection-site Swelling20.237.5
Statistical analysis
  • Heterosexual and MSM Males vs Females · Miettinen & Nurminen · p = <0.001 · Risk difference (rd): -11.5 · 95% CI -15.0 to -8.0The incidence of AEs of injection-site erythema reported on the Vaccination Report Card was compared between heterosexual / MSM male participants and female participants
  • Heterosexual and MSM Males vs Females · Miettinen & Nurminen · p = <0.001 · Risk difference (rd): -19.1 · 95% CI -22.5 to -15.7The incidence of AEs of injection-site erythema reported on the Vaccination Report Card was compared between heterosexual / MSM male participants and female participants
  • Heterosexual and MSM Males vs Females · Miettinen & Nurminen · p = <0.001 · Risk difference (rd): -17.3 · 95% CI -20.8 to -13.7The incidence of AEs of injection-site erythema reported on the Vaccination Report Card was compared between heterosexual / MSM male participants and female participants
PrimaryPercentage of Participants With Elevated Oral Body Temperature (>=37.8° C, >=100° F)

Participants were instructed by the investigator to use the Vaccination Report Card to document evening oral temperature daily after each study vaccination

Time frame:
Up to 5 days after any vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With Elevated Oral Body Temperature (>=37.8° C, >=100° F)
Percentage of ParticipantsHeterosexual and MSM MalesFemales
Percentage of Participants With Elevated Oral Body Temperature (>=37.8° C, >=100° F)4.45.9
Statistical analysis
  • Heterosexual and MSM Males vs Females · Miettinen & Nurminen · p = 0.091 · Risk difference (rd): -1.5 · 95% CI -3.4 to 0.2The incidence of maximum body temperature \>=37.8° C reported on the Vaccination Report Card was compared between heterosexual / MSM male participants and female participants
SecondaryPercentage of Participants With Seroconversion to the HPV Types Contained in the 9vHPV Vaccine

Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24; HPV Type 31: ≥10; HPV Types 33, 45, 52, and 58: ≥8.

Time frame:
Four weeks post vaccination 3 (Month 7)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Seroconversion to the HPV Types Contained in the 9vHPV Vaccine
Percentage of ParticipantsHeterosexual MalesFemalesMen Who Have Sex With Men
Anti-HPV Type 6 (n=847, 708, 164)99.6 (99.0 to 99.9)99.6 (98.8 to 99.9)99.4 (96.6 to 100)
Anti-HPV Type 11 (n=851, 712, 165)100 (99.6 to 100)99.9 (99.2 to 100)100 (97.8 to 100)
Anti-HPV Type 16 (n=899, 781, 212)100 (99.6 to 100)99.9 (99.3 to 100)100 (98.3 to 100)
Anti-HPV Type 18 (n=906, 831, 220)99.9 (99.4 to 100)99.8 (99.1 to 100)99.5 (97.5 to 100)
Anti-HPV Type 31 (n=908, 826, 227)100 (99.6 to 100)100 (99.6 to 100)100 (98.4 to 100)
Anti-HPV Type 33 (n=901, 853, 230)100 (99.6 to 100)99.9 (99.3 to 100)100 (98.4 to 100)
Anti-HPV Type 45 (n=909, 871, 232)99.8 (99.2 to 100)99.5 (98.8 to 99.9)100 (98.4 to 100)
Anti-HPV Type 52 (n=907, 849, 232)100 (99.6 to 100)99.8 (99.2 to 100)100 (98.4 to 100)
Anti-HPV Type 58 (n=897, 839, 223)100 (99.6 to 100)99.8 (99.1 to 100)100 (98.4 to 100)
Statistical analysis
  • Heterosexual Males vs Females · Miettinen & Nurminen · p = <0.001 · Risk difference (rd): 0.1 · 95% CI -0.7 to 0.9
  • Heterosexual Males vs Females · Miettinen & Nurminen · p = <0.001 · Risk difference (rd): 0.1 · 95% CI -0.3 to 0.8
  • Heterosexual Males vs Females · Miettinen & Nurminen · p = <0.001 · Risk difference (rd): 0.1 · 95% CI -0.3 to 0.7
  • Heterosexual Males vs Females · Miettinen & Nurminen · p = <0.001 · Risk difference (rd): 0.1 · 95% CI -0.4 to 0.8
  • Heterosexual Males vs Females · Miettinen & Nurminen · p = <0.001 · Risk difference (rd): 0.0 · 95% CI -0.4 to 0.5
  • Heterosexual Males vs Females · Miettinen & Nurminen · p = <0.001 · Risk difference (rd): 0.1 · 95% CI -0.3 to 0.7
  • Heterosexual Males vs Females · Miettinen & Nurminen · p = <0.001 · Risk difference (rd): 0.2 · 95% CI -0.4 to 1.0
  • Heterosexual Males vs Females · Miettinen & Nurminen · p = <0.001 · Risk difference (rd): 0.2 · 95% CI -0.2 to 0.9
  • Heterosexual Males vs Females · Miettinen & Nurminen · p = <0.001 · Risk difference (rd): 0.2 · 95% CI -0.2 to 0.9
PrimaryPercentage of Participants With an Adverse Event

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE.

Time frame:
Up to Month 12
Reported as:
Number · Percentage of Participants
Percentage of Participants With an Adverse Event
Percentage of ParticipantsHeterosexual and MSM MalesFemales
Percentage of Participants With an Adverse Event76.289.4
PrimaryPercentage of Participants Who Had Study Vaccine Discontinued Due to an Adverse Event

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE.

Time frame:
Up to Month 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Had Study Vaccine Discontinued Due to an Adverse Event
Percentage of ParticipantsHeterosexual and MSM MalesFemales
Percentage of Participants Who Had Study Vaccine Discontinued Due to an Adverse Event0.10.3

Adverse events

Collected over Up to Month 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Heterosexual and MSM Males—23/1,394 (1.6%)976/1,394 (70%)
Females—26/1,075 (2.4%)924/1,075 (86%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventHeterosexual and MSM MalesFemales
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/13944/1075
Abortion inducedSurgical and medical procedures0/13944/1075
ConstipationGastrointestinal disorders0/13942/1075
Ectopic pregnancyPregnancy, puerperium and perinatal conditions0/13942/1075
AppendicitisInfections and infestations2/13941/1075
ConcussionInjury, poisoning and procedural complications2/13940/1075
VomitingGastrointestinal disorders0/13941/1075
Cyst ruptureGeneral disorders0/13941/1075
CholecystitisHepatobiliary disorders0/13941/1075
Appendicitis perforatedInfections and infestations0/13941/1075
Most frequent other events
Most frequent other events
EventHeterosexual and MSM MalesFemales
Injection site painGeneral disorders886/1394893/1075
Injection site swellingGeneral disorders285/1394408/1075
Injection site erythemaGeneral disorders291/1394348/1075
HeadacheNervous system disorders200/1394246/1075

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Heterosexual MalesFemalesMen Who Have Sex With Men (MSM)Total
Mean20.8 ± 3.021.3 ± 2.922.2 ± 2.421.2 ± 2.9
Sex: Female, Male
Sex: Female, Male(Participants)Heterosexual MalesFemalesMen Who Have Sex With Men (MSM)Total
Female0110101101
Male110603131419
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Castellsague X, Giuliano AR, Goldstone S, Guevara A, Mogensen O, Palefsky JM, Group T, Shields C, Liu K, Maansson R, Luxembourg A, Kaplan SS. Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 2015 Nov 27;33(48):6892-901. doi: 10.1016/j.vaccine.2015.06.088. Epub 2015 Jul 2. PubMed 26144901 ↗
  • Moreira ED Jr, Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, Bosch FX, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Qi H, Hyatt D, Martin J, Moeller E, Ritter M, Baudin M, Luxembourg A. Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. Pediatrics. 2016 Aug;138(2):e20154387. doi: 10.1542/peds.2015-4387. Epub 2016 Jul 15. PubMed 27422279 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2012 to primary completion in Aug 2014, 21 months.

Results were first posted in Mar 2015, 7 months after primary completion.

Of 28 phase 3 interventional studies under Condylomata Acuminata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2012
First posted
Jul 27, 2012
StartActual
Oct 29, 2012
Primary completionActual
Aug 4, 2014
CompletionActual
Aug 4, 2014
Results first posted
Mar 9, 2015
Last update
Nov 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01651949
Responsible party
Sponsor
First posted
Jul 27, 2012
Start date
Oct 29, 2012
Primary completion
Aug 4, 2014
Completion
Aug 4, 2014
Results posted
Mar 9, 2015
Last update
Nov 27, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion